产品描述
| 溶解性 |
|
| 存贮条件 | 储存温度-20°C |
| 产品介绍 | Canagliflozin inhibits Na+- dependent 14C-AMG uptake in a concentration-dependent fashion. It is a novel C-glucoside with thiophene ring. |
| 备注 | Canagliflozin is a highly potent and selective SGLT2 inhibitor for hSGLT2 with IC50 of 2.2 nM, exhibits 413-fold selectivity over hSGLT1. |
| 生化机理 |
Canagliflozin(JNJ 24831754ZAE; JNJ 28431754; JNJ 28431754AAA; TA 7284) is an experimental drug being developed by Johnson & Johnson for the treatment of type 2 diabetes.Canagliflozin(JNJ 24831754ZAE; JNJ 28431754; JNJ 28431754AAA; TA 7284) is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine. |
| 别名 | 坎格列净;(1S)-1,5-脱氢-1-C-[3-[[5-(4-氟苯基)-2-噻吩基]甲基]-4-甲基苯基]-D-葡萄糖醇;JNJ 24831754ZAE; JNJ 28431754; JNJ 28431754AAA; TA 7284;(2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol |
